Nilotinib Stada (Nilotinib)

Nilotinib works by selectively binding to the ATP‑binding pocket of the BCR‑ABL tyrosine kinase, locking the enzyme in an inactive state. This blocks downstream signaling that drives uncontrolled cell growth, thereby reducing the proliferation of leukemic cells that depend on the BCR‑ABL pathway.

The dosing regimen for Nilotinib Stada is individualized by the prescribing clinician based on the patient’s disease status, prior therapy, and overall health. The prescriber determines the appropriate dose, schedule, and any necessary adjustments.

Safety data for Nilotinib during pregnancy and lactation are limited, and the drug may pose risks to the fetus or infant. It is generally avoided in pregnant or nursing women, and effective contraception is recommended for women of child‑bearing potential during treatment.

To order Nilotinib Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Nilotinib is a second‑generation BCR‑ABL inhibitor offering higher potency and activity against many imatinib‑resistant mutations. Compared with imatinib, it often achieves faster and deeper molecular responses, though it may carry a higher risk of QT prolongation and requires careful cardiac monitoring.

Store Nilotinib Stada tablets at temperatures below 25 °C in the original container, protecting them from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing the tablets to excessive heat or humidity.

Nilotinib Stada is taken orally as a tablet, usually with a low‑fat meal or as directed by the prescriber. The tablets should be swallowed whole with water and not crushed or chewed, unless the prescribing information states otherwise.

The most serious adverse events include QT interval prolongation, which can lead to serious cardiac arrhythmias, severe hepatic injury, pancreatitis, and marked neutropenia or thrombocytopenia that increase infection or bleeding risk. Patients should report any chest pain, unusual fatigue, jaundice, severe abdominal pain, or signs of infection promptly.

Nilotinib Stada should be avoided in patients with known hypersensitivity to Nilotinib or any excipients, those with a history of prolonged QT interval, severe hepatic impairment, or uncontrolled cardiac disease. It is also contraindicated in pregnant women and generally not recommended for breastfeeding mothers.